AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Recruitingn/aAges 12 Years - anyAllGalderma R&D
💬

In plain words

What the trial is, and whether it could suit you

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®). * Adolescent and adult participants aged \>=12 years with moderate-to-severe AD. * Participants who signed the written informed consent form (ICF) or had it signed by their legal representative. Exclusion Criteria: * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label. * Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline. * Participants who received nemolizumab previously. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
💊

What it tests

  • Not listed
📍

Where

108 sites
Galderma Investigational Site - 8893
Birmingham, United States
Galdrma Investigational Site - 7077
Phoenix, United States
Galderma Investigational Site 7060
Phoenix, United States
Galderma Investigational Site - 8535
Phoenix, United States
Galderma Investigational Site - 7067
Tucson, United States
Galderma Investigational Site - 7074
Corona, United States
Galderma Investigational Site 8636
Fountain Valley, United States
Galderma Investigational Site 8224
Fremont, United States

…and 100 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy